Azora Replaces Entire Board and Converts 9.9M Preferred Shares Into Common
Summary
Azora appointed three independent directors and lost four legacy Adial directors, cutting the board to five, while 9.9 million Series A preferred shares converted into common stock, leaving 14,243,129 shares outstanding.
Key Events · Executive and Board Changes · ADIL
-
Board Overhauled With Three New Directors
Aida Habtezion, Paul Hastings and Thomas Soloway joined as independent directors on November 3, 2026, while J. Kermit Anderson, Cary Claiborne, Robertson Gilliland and Kevin Schuyler resigned; the board was cut to five members and Matthew Davidson named chair.
-
Series A Preferred Converts to Common
Effective 5:00 p.m. Eastern on November 2, 2026, 9,924.260 Series A Preferred shares automatically converted into 9,924,260 common shares, leaving 3,006.341 preferred shares outstanding due to beneficial ownership limits.
-
Shares Outstanding Reach 14,243,129
Following the conversion, the company reported 14,243,129 common shares outstanding as of November 4, 2026.
-
Conversion Already Approved October 28
Stockholders approved the issuance for Nasdaq Rules 5635(a) and 5635(b) at the reconvened 2026 Annual Meeting on October 28, 2026, so the dilution was previously authorized.
Analysis · ADIL · Life Sciences
Six days after completing its rebrand, Azora replaced most of its board, installing three independent directors with big-pharma and biotech operating backgrounds while four legacy Adial directors stepped down and the board shrank to five. Separately, 9,924,260 Series A preferred shares converted into common stock, lifting shares outstanding to 14,243,129 as of November 4, with 3,006.341 preferred shares still held back by ownership caps. Because stockholders already approved the conversion on October 28, the dilution is expected rather than new; the board overhaul, by contrast, is a genuine governance reset that puts the former Azora team firmly in control.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADIL was trading at $4.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.3M. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.